Crawford ED - Search Results

1

Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis.

Uemura M, Kikukawa H, Hashimoto Y, Uemura H, Mizokami A, Kato M, Matsushima H, Kosaka T, Nakamura M, Fukasawa S, Smith MR, Tombal B, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kakiuchi H, Akiyama M, Li R, Kuss I, Joensuu H, Suzuki H. Uemura M, et al. Among authors: crawford ed. Cancer Med. 2024 Nov;13(21):e70029. doi: 10.1002/cam4.70029. Cancer Med. 2024. PMID: 39527466 Free PMC article. Clinical Trial.

2

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.

Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R; ELM-PC 4 investigators. Saad F, et al. Lancet Oncol. 2015 Mar;16(3):338-48. doi: 10.1016/S1470-2045(15)70027-6. Epub 2015 Feb 18. Lancet Oncol. 2015. PMID: 25701170 Clinical Trial.

3

Cases in the management of prostate cancer: the addition of darolutamide to androgen deprivation therapy and docetaxel in a 55-year-old man with metastatic hormone-sensitive prostate cancer.

Crawford ED. Crawford ED. Clin Adv Hematol Oncol. 2022 Jul;20 Suppl 14(7):1-8. Clin Adv Hematol Oncol. 2022. PMID: 35905311 No abstract available.

4

Monotherapy versus combined androgen blockade in patients with advanced prostate cancer.

Errejon A, Crawford ED. Errejon A, et al. Among authors: crawford ed. Cancer. 2002 Jul 15;95(2):209-10. doi: 10.1002/cncr.10648. Cancer. 2002. PMID: 12124816 Free article. No abstract available.

5

Characterising the castration-resistant prostate cancer population: a systematic review.

Kirby M, Hirst C, Crawford ED. Kirby M, et al. Among authors: crawford ed. Int J Clin Pract. 2011 Nov;65(11):1180-92. doi: 10.1111/j.1742-1241.2011.02799.x. Int J Clin Pract. 2011. PMID: 21995694 Review.

6

Review of the economic evaluations of hormonal therapy for patients with locally advanced prostate cancer.

Hatoum HT, Crawford ED, Nielsen SK, Lin SJ, Marshall DC. Hatoum HT, et al. Among authors: crawford ed. Expert Rev Pharmacoecon Outcomes Res. 2013 Apr;13(2):251-9. doi: 10.1586/erp.13.12. Expert Rev Pharmacoecon Outcomes Res. 2013. PMID: 23570436 Review.

7

Advanced prostate cancer.

Waxman SW, Crawford ED. Waxman SW, et al. Among authors: crawford ed. Surg Technol Int. 1995;IV:266-70. Surg Technol Int. 1995. PMID: 21400446

8

Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer.

Dorff TB, Crawford ED. Dorff TB, et al. Among authors: crawford ed. Ann Oncol. 2013 Jan;24(1):31-8. doi: 10.1093/annonc/mds216. Epub 2012 Jul 24. Ann Oncol. 2013. PMID: 22831986 Free article. Review.

9

Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer.

Hatoum HT, Crawford ED, Nielsen SK, Lin SJ, Marshall DC. Hatoum HT, et al. Among authors: crawford ed. Expert Rev Pharmacoecon Outcomes Res. 2013 Apr;13(2):261-70. doi: 10.1586/erp.13.13. Expert Rev Pharmacoecon Outcomes Res. 2013. PMID: 23570437 Clinical Trial.

10

Small steps that lead to a giant leap for prostate cancer patients.

Crawford ED. Crawford ED. Oncology (Williston Park). 2014 Aug;28(8):652. Oncology (Williston Park). 2014. PMID: 25140622 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

653 results

Search Page

Filters